Shares of Exact Sciences rose sharply Thursday after Abbott Laboratories agreed to purchase the cancer screening company in a ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking ...

Abbott Laboratories $21 billion deal to acquire cancer test maker Exact Sciences could bolster the company’s diagnostic ...

Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Click here to read what this means for ABT ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...

We recently published 10 Stocks Jim Cramer Talked About. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer ...

By bringing Exact Sciences into the fold, the expectation is that the focus on cancer diagnostics can provide a jolt to the ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share. Click here ...

Global healthcare leader Abbott announced Thursday that it has reached a $23 billion deal to acquire Exact Sciences.

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

Abbott is buying Exact Sciences, the maker of tests designed to detect early cancers, in a $21 billion deal, a sign of ...

Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its ...